Remegen, Ltd.

Remegen Co., Ltd.

Tongji University

Yantai Rc Biotechnologies, Ltd.

Jianmin Fang

Jing Jiang

Dong Li

Changjiang Huang

Xuejing Yao

Qiaoyu Xu

Wenting Luo

Hui Ye

Ming Jiang

Ling Wang

Qiaohua Hou

Guorui Zhao

Shenjun Li

Mingxue Wang

Xiuzhi Zhan

Nan Shen

Hu Chen

Yanxin Yin

Jia Guo

Lihua Yu

Xuejing Luan

Zhuanglin Li

Hongwen Li

Qianjing Bao

Shizhong Zhai

Haohua Jie

Provided in the present invention is a PD-L1 immunosuppressant, and specifically provided are a monoclonal antibody capable of targeting PD-L1, and nucleotides, combinations of polynucleotides, expression vectors and combinations of expression vectors encoding the antibody. Also provided in the present invention is a conjugate or pharmaceutical composition containing the above-mentioned anti PD-L1 antibody. Further provided in the present invention is the use of the above-mentioned anti PD-L1 antibody, nucleotides, combinations of polynucleotides, expression vectors, combinations of expression vectors, conjugate or pharmaceutical composition in the preparation of a medicament for treating or preventing cancers.

Anti PD-L1 antibody and use thereof

The present invention provides a linker for preparing antibody-drug conjugates and antibody-drug conjugates prepared by the linker, as well as use of the antibody-drug conjugates in a medicament for treating tumor. The linker is capable of coupling simultaneously with the thiol group or amino group on the antibody or functional fragment of the antibody, especially it is capable of coupling with 2, 3 or 4 thiol groups on the antibody or functional fragment of the antibody. A coupled product is uniform and structurally stable.

Linker for antibody-drug conjugates and its use

The present invention discloses an antibody drug conjugate that targets MSLN. The present invention also disclosed a method of making the antibody drug conjugate (ADC). The present invention further discloses a novel MSLN antibody or a functional fragment thereof comprising engineered heavy and light chains.

Anti-mesothelin antibody and antibody drug conjugate thereof

A method for treating or preventing vascular endothelial cell injured diseases, especially cerebral infarctions or myocardial infarctions, by administering a c-MET agonist antibody to a subject in need thereof, and specific c-MET agonist antibodies.

C-MET agonistic antibody and use thereof

The present invention relates to a bifunctional angiogenesis inhibitor, which has VEGF inhibitory activity and FGF inhibitory activity, and can inhibit VEGF and FGF dual factors-induced or high glucose-induced cell proliferation, cell migration, and/or lumen formation. The present invention also relates to the use of the bifunctional angiogenesis inhibitor in inhibiting retinal angiogenesis, such as diabetic retinopathy, age-related macular degeneration and the like.

Bifunctional angiogenesis inhibitor and use thereof

Disclosed are an anti-HER2 antibody and conjugate of the anti-HER2 antibody and small molecule medicine. Also disclosed are uses of the antibody and conjugate thereof in preparing medicine for treating tumor.

Anti-HER2 antibody and conjugate thereof

The present invention belongs to the field of biotechnology and relates to the treatment of diseases, especially the treatment of FGF overexpression-related diseases. Particularly, the present invention relates to FGFR-Fc fusion proteins and the use thereof in the treatment of angiogenesis regulation-related diseases. More particularly, the present invention relates to isolated soluble FGFR-Fc fusion proteins and their applications in manufacture of the medicament for the treatment of angiogenesis regulation-related diseases.

FGFR-FC fusion proteins and the use thereof

The present invention relates to angiogenesis-inhibitory fusion proteins and use thereof. Particularly, the present invention provides fusion proteins inhibiting a plurality of angiogenic factors. More particularly, the present invention relates to the fusion proteins of VEGF receptor and FGF receptor and their applications in the treatment of angiogenesis related diseases.

Fusion protein for antagonizing angiogenesis inducible factors and uses thereof

FGFR-Fc fusion proteins and the use thereof

Growing community of inventors

Yantai, China

Jianmin Fang